HK1159133A1 - Fgf-r4 receptor-specific antagonists fgf-r4 - Google Patents

Fgf-r4 receptor-specific antagonists fgf-r4

Info

Publication number
HK1159133A1
HK1159133A1 HK11113762.6A HK11113762A HK1159133A1 HK 1159133 A1 HK1159133 A1 HK 1159133A1 HK 11113762 A HK11113762 A HK 11113762A HK 1159133 A1 HK1159133 A1 HK 1159133A1
Authority
HK
Hong Kong
Prior art keywords
fgf
receptor
specific antagonists
antagonists
specific
Prior art date
Application number
HK11113762.6A
Other languages
English (en)
Chinese (zh)
Inventor
Nicolas Baurin
Pierre-Franois Berne
Francis Blanche
Franoise Bono
Batrice Cameron
Tarik Dabdoubi
Corentin Herbert
Vincent Mikol
Elisabeth Remy
Original Assignee
賽諾菲-安萬特
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40626849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1159133(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 賽諾菲-安萬特 filed Critical 賽諾菲-安萬特
Publication of HK1159133A1 publication Critical patent/HK1159133A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK11113762.6A 2008-07-08 2011-12-21 Fgf-r4 receptor-specific antagonists fgf-r4 HK1159133A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0803888A FR2933702A1 (fr) 2008-07-08 2008-07-08 Antagonistes specifiques du recepteur fgf-r4
PCT/FR2009/051343 WO2010004204A2 (fr) 2008-07-08 2009-07-07 Antagonistes specifiques du recepteur fgf-r4

Publications (1)

Publication Number Publication Date
HK1159133A1 true HK1159133A1 (en) 2012-07-27

Family

ID=40626849

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11113762.6A HK1159133A1 (en) 2008-07-08 2011-12-21 Fgf-r4 receptor-specific antagonists fgf-r4

Country Status (38)

Country Link
US (1) US20110150903A1 (es)
EP (1) EP2315781B1 (es)
JP (2) JP5726731B2 (es)
KR (1) KR20110028536A (es)
CN (2) CN102149730B (es)
AR (1) AR072699A1 (es)
AU (1) AU2009267834B2 (es)
BR (1) BRPI0915660A2 (es)
CA (1) CA2730300A1 (es)
CL (1) CL2011000047A1 (es)
CO (1) CO6440535A2 (es)
CR (1) CR11868A (es)
CY (1) CY1116847T1 (es)
DK (1) DK2315781T3 (es)
DO (1) DOP2011000005A (es)
EA (2) EA021580B1 (es)
EC (1) ECSP11010748A (es)
ES (1) ES2544761T3 (es)
FR (1) FR2933702A1 (es)
HK (1) HK1159133A1 (es)
HN (1) HN2011000074A (es)
HR (1) HRP20150836T1 (es)
HU (1) HUE027221T2 (es)
IL (1) IL210516A0 (es)
MA (1) MA32547B1 (es)
MX (1) MX2011000328A (es)
NI (1) NI201100012A (es)
NZ (2) NZ590860A (es)
PE (1) PE20110313A1 (es)
PL (1) PL2315781T3 (es)
PT (1) PT2315781E (es)
SG (1) SG10201403751XA (es)
SI (1) SI2315781T1 (es)
TW (1) TW201006492A (es)
UA (1) UA107782C2 (es)
UY (1) UY31970A (es)
WO (1) WO2010004204A2 (es)
ZA (1) ZA201100209B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107090045A (zh) * 2010-05-03 2017-08-25 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
EP3050899B1 (en) * 2010-09-27 2019-09-04 Janssen Biotech, Inc. Antibodies binding human collagen ii
KR20140021589A (ko) * 2011-04-07 2014-02-20 제넨테크, 인크. 항-fgfr4 항체 및 사용 방법
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
US20140294820A1 (en) * 2011-06-24 2014-10-02 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
ES2828505T3 (es) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
NZ630469A (en) 2012-12-27 2017-02-24 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2014105849A1 (en) * 2012-12-28 2014-07-03 Xoma (Us) Llc Antibodies specific for fgfr4 and methods of use
WO2014165287A1 (en) * 2013-03-12 2014-10-09 The Translational Genomics Research Institute Hybridoma clones and monoclonal antibodies to fibroblast growth factor 4
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
AU2014338549B2 (en) 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
EP3062881B1 (en) 2013-10-28 2019-10-02 NGM Biopharmaceuticals, Inc. Cancer models and associated methods
TW201612518A (en) * 2014-01-17 2016-04-01 Sanofi Sa Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody
PL3097122T3 (pl) 2014-01-24 2020-10-19 Ngm Biopharmaceuticals, Inc. Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
TR201909951T4 (tr) 2014-07-18 2019-07-22 Sanofi Sa Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
CN104177492B (zh) * 2014-07-21 2017-02-22 暨南大学 FGFR2c胞外段类似物及其编码基因与应用
JP7011939B2 (ja) * 2014-08-11 2022-01-27 ダイイチサンキョウヨーロッパ ゲーエムベーハー ヒト抗－ｆｇｆｒ４抗体
JP6585167B2 (ja) 2014-10-03 2019-10-02 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
JP6949711B2 (ja) 2014-10-23 2021-10-20 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド ペプチドバリアントを含む医薬組成物及びその使用方法
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
JP6695353B2 (ja) 2015-03-25 2020-05-20 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体
EP3095465A1 (en) 2015-05-19 2016-11-23 U3 Pharma GmbH Combination of fgfr4-inhibitor and bile acid sequestrant
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
EP3888672A1 (en) 2015-11-09 2021-10-06 NGM Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
CN109071659B (zh) 2016-02-10 2022-06-10 生物发明国际股份公司 人抗fgfr4抗体和索拉非尼的组合
BR112018067458A2 (pt) * 2016-03-04 2019-01-02 Abmuno Therapeutics Llc anticorpos para tigit
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
IL266293B (en) 2016-11-02 2022-07-01 Novartis Ag Combinations of fgfr4 inhibitors and bile acid sequestrants
EP3544998A1 (en) * 2016-11-22 2019-10-02 Merck Patent GmbH Monoclonal antibody directed to fgfr1
EP3444275A1 (en) * 2017-08-16 2019-02-20 Exiris S.r.l. Monoclonal antibody anti-fgfr4
CN109725159B (zh) * 2018-12-28 2021-10-08 江苏众红生物工程创药研究院有限公司 人β2-微球蛋白的定量检测试纸卡与临床应用
JP2023511236A (ja) * 2020-01-21 2023-03-16 タボテック バイオセラピューティクス （ホンコン） リミテッド ＩＬ－１β受容体シグナル伝達に干渉する剤
CA3176246A1 (en) 2020-06-02 2021-12-09 Arcus Biosciences, Inc. Antibodies to tigit
WO2022098662A2 (en) * 2020-11-03 2022-05-12 Twist Bioscience Corporation Methods and compositions relating to chemokine receptor variants
CN118108840A (zh) * 2022-11-29 2024-05-31 中国科学院深圳先进技术研究院 抗fgfr4单克隆抗体、靶向fgfr4的嵌合抗原受体t细胞及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DE60031793T2 (de) * 1999-12-29 2007-08-23 Immunogen Inc., Cambridge Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
CA2542638A1 (en) * 2003-10-16 2005-04-28 Imclone Systems Incorporated Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
CA2637988A1 (en) * 2006-02-10 2007-11-29 Genentech, Inc. Anti-fgf19 antibodies and methods using same
US8394927B2 (en) * 2006-11-03 2013-03-12 U3 Pharma Gmbh FGFR4 antibodies
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
AU2008226582B2 (en) * 2007-03-09 2011-07-21 Novartis Ag Treatment of melanoma

Also Published As

Publication number Publication date
PE20110313A1 (es) 2011-06-21
DK2315781T3 (en) 2015-08-10
SG10201403751XA (en) 2014-09-26
HN2011000074A (es) 2013-01-28
IL210516A0 (en) 2011-03-31
CA2730300A1 (fr) 2010-01-14
PL2315781T3 (pl) 2015-10-30
HRP20150836T1 (hr) 2015-09-11
EP2315781A2 (fr) 2011-05-04
EA201401107A1 (ru) 2015-05-29
PT2315781E (pt) 2015-09-21
ES2544761T3 (es) 2015-09-03
NZ602905A (en) 2014-05-30
AU2009267834A1 (en) 2010-01-14
MA32547B1 (fr) 2011-08-01
JP2015057398A (ja) 2015-03-26
NI201100012A (es) 2011-07-20
WO2010004204A2 (fr) 2010-01-14
UA107782C2 (ru) 2015-02-25
TW201006492A (en) 2010-02-16
ECSP11010748A (es) 2011-02-28
HUE027221T2 (en) 2016-10-28
EP2315781B1 (fr) 2015-05-06
CN102149730A (zh) 2011-08-10
US20110150903A1 (en) 2011-06-23
WO2010004204A3 (fr) 2010-04-29
EA021580B1 (ru) 2015-07-30
FR2933702A1 (fr) 2010-01-15
EA201170155A1 (ru) 2011-08-30
JP5726731B2 (ja) 2015-06-03
UY31970A (es) 2010-02-26
ZA201100209B (en) 2012-04-25
DOP2011000005A (es) 2011-02-15
CN103784954A (zh) 2014-05-14
AU2009267834B2 (en) 2014-10-23
CY1116847T1 (el) 2017-03-15
CN102149730B (zh) 2014-03-26
NZ590860A (en) 2012-12-21
MX2011000328A (es) 2011-04-05
AR072699A1 (es) 2010-09-15
SI2315781T1 (sl) 2015-09-30
BRPI0915660A2 (pt) 2019-08-27
CR11868A (es) 2011-02-16
KR20110028536A (ko) 2011-03-18
CO6440535A2 (es) 2012-05-15
CL2011000047A1 (es) 2011-07-08
JP2011527322A (ja) 2011-10-27

Similar Documents

Publication Publication Date Title
HK1159133A1 (en) Fgf-r4 receptor-specific antagonists fgf-r4
HUS2200025I1 (hu) C5AR antagonisták
IL219390A0 (en) Il-17a antagonists
IL195909A0 (en) Pan-cell surface receptor-specific therapeutics
HK1143994A1 (en) Glucagon antagonists
HK1203481A1 (en) Glucagon antagonists
EP2312947A4 (en) TRPV4 Antagonist
ZA200906812B (en) Crig antagonists
EP2277678A4 (en) EXTERNAL COMPONENT
EP2478011A4 (en) FLUORINATED GHRH ANTAGONISTS
HK1149205A1 (en) Methods for inhibiting angiogenesis using egfl8 antagonists
ZA201008177B (en) Substituted quinazolines
EP2365748A4 (en) IMIDAZOISOINDOLA ANTAGONISTS OF NEUROPEPTIDE S RECEPTORS
GB0808947D0 (en) Substituted quinazolines
GB0808944D0 (en) Substituted quinazolines
GB0808967D0 (en) Substitute quinazolines
GB0808950D0 (en) Substituted quinazolines
GB0808951D0 (en) Substituted quinazolines
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists
GB0810005D0 (en) Substituted quinazolines
GB0808953D0 (en) substituted quinazolines
GB0808952D0 (en) Substituted quinazolines
GB0808968D0 (en) Substitute quinazolines
GB2457363B (en) Demarcation apparatus
GB0701632D0 (en) MET receptor antagonists

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180707